We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Catalyst Pharmaceutical Inc (CPRX) Com Stk USD0.001

Sell:$21.74 Buy:$22.88 Change: $0.02 (0.09%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$21.74
Buy:$22.88
Change: $0.02 (0.09%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$21.74
Buy:$22.88
Change: $0.02 (0.09%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Contact details

Address:
355 ALHAMBRA CIRCLE, SUITE 801
CORAL GABLES
33134
United States
Telephone:
+1 (305) 5292522
Website:
https://catalystpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CPRX
ISIN:
US14888U1016
Market cap:
$2.61 billion
Shares in issue:
119.27 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Richard Daly
    Chief Executive Officer, Director
  • Michael Kalb
    Chief Financial Officer, Executive Vice President, Treasurer
  • Steven Miller
    Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
  • Jeffrey Del Carmen
    Executive Vice President, Chief Commercial Officer
  • Brian Elsbernd
    Chief Compliance Officer, Chief Legal Officer
  • Gary Ingenito
    Chief Medical Officer and Regulatory Officer
  • Preethi Sundaram
    Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.